Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study

Cancer

Volumn 123, Issue 6, 2017, Pages 1011-1017

  Gulhati, Pat ^a   Raghav, Kanwal ^a   Shroff, Rachna T ^a   Varadhachary, Gauri R ^a   Kopetz, Scott ^a   Javle, Milind ^a   Qiao, Wei ^a   Wang, Huamin ^a   Morris, Jeffrey ^a   Wolff, Robert A ^a   Overman, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ampullary adenocarcinoma; bevacizumab; capecitabine with oxaliplatin (CAPOX); small bowel adenocarcinoma; small bowel cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CREATININE; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMPULLARY ADENOCARCINOMA; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PORTAL HYPERTENSION; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SMALL BOWEL ADENOCARCINOMA; SMALL INTESTINE CARCINOMA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; AMPULLA OF VATER; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COMMON BILE DUCT NEOPLASMS; COMORBIDITY; INTESTINAL NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SMALL INTESTINE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AMPULLA OF VATER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAPECITABINE; COMMON BILE DUCT NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 85005950577     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30445     Document Type: Article

References (15)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013;10:534–544.
3. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10:132–137.
4. Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27:2598–2603.
5. McWilliams RR, Mahoney MR, Marchello BT, et al. Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) trial. J Clin Oncol. 2012;30(suppl 4):a314.
6. Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23:561–566.
7. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–591.
8. Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102:144–150.
9. Von Rahden BH, Brucher BL, Langner C, Siewert JR, Stein HJ, Sarbia M. Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. Br J Surg. 2006;93:1424–1432.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
11. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
13. Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012;19:1439–1445.
14. Fu T, Pappou EP, Guzzetta AA, et al. CpG island methylator phenotype–positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Clin Cancer Res. 2012;18:4743–4752.
15. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–3976.